modelV09DA05
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Technetium99mtcGaltifenin | |
| ATC code: | V09DA05 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 74 | mg |
| volume of distribution: | 0.15 | L |
| clearance: | 0.12 | L/h/kg |
| other parameters in model implementation | ||
Technetium (99mTc) galtifenin is a radiopharmaceutical used in nuclear medicine primarily as a hepatobiliary imaging agent to assess liver and gallbladder function. It is used in diagnostic imaging (cholescintigraphy) to evaluate biliary tract patency and gallbladder ejection fraction. This drug is not approved or widely used in clinical practice today, with limited historical or investigational usage.
Pharmacokinetics
No published pharmacokinetic data in humans or animals could be found. All pharmacokinetic parameters are estimated based on the class of technetium-99m labeled hepatobiliary agents and general properties of similar compounds.
References
Castronovo, FP (1981). Normal pharmacokinetics of 99mTc-diphosphonate after intravenous administration. Biopharmaceutics & drug disposition 2(3) 283–289. DOI:10.1002/bdd.2510020309 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7295885
Wong, M, et al., & Gurney, H (2006). Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 24(16) 2448–2455. DOI:10.1200/JCO.2005.02.1295 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16651648
Castagnetti, M, et al., & Buxton-Thomas, M (2007). Hepatobiliary scintigraphy after Kasai procedure for biliary atresia: clinical correlation and prognostic value. Journal of pediatric surgery 42(6) 1107–1113. DOI:10.1016/j.jpedsurg.2007.01.063 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17560230
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)